RUPPIIS

Ruthenium Based Protein-Protein Interaction Inhibitor’s

Coordinatore	UNIVERSITY OF LEEDS    more  Organization address address: WOODHOUSE LANE city: LEEDS postcode: LS2 9JT contact info Titolo: Mr. Nome: Martin Cognome: Hamilton Email: send email Telefono: +44 113 343 4090 Fax: +44 113 343 0949
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	221˙606 €
EC contributo	221˙606 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2012-IEF
Funding Scheme	MC-IEF
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-10-01   -   2015-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY OF LEEDS  Organization address address: WOODHOUSE LANE city: LEEDS postcode: LS2 9JT contact info Titolo: Mr. Nome: Martin Cognome: Hamilton Email: send email Telefono: +44 113 343 4090 Fax: +44 113 343 0949	UK (LEEDS)	coordinator	221˙606.40

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'In this research, the fellow (Jayapal Reddy Mallareddy) will synthesize novel cell permeable fluorescent ruthenium complexes and demonstrate their utility for perturbing biological processes. This fellowship will build on the fellows expertise in synthetic chemistry (particularly peptide synthesis) applied at the biological interface, together with Leeds’ expertise in the design and synthesis of cell permeable inhibitors of protein-protein interactions. The project will ultimately furnish cell permeable fluorescent small molecules designed to act as inhibitors of key protein-protein interactions involved in disease development and progression. Such inhibitors can be used as tool molecules to understand biological processes, as sensors for malfunctioning proteins and as the starting point for development of new molecular therapeutics thus impacting the competitiveness of the EU, and the quality of life of its citizens, by facilitating new strategies for diagnosing and treating disease.'